Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020

Rheumatoid Arthritis

Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry

Arthritis Care Res (Hoboken).

Winthrop KL, Saag K, Cascino MD, Pei J, John A, Jahreis A, Haselkorn T, Furst DE

doi: 10.1002/acr.23781.

Rheumatoid Arthritis

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry

Rheumatol Ther.

Pappas DA, Kremer JM, Griffith J, Reed G, Salim B, Karki C, Garg V

doi: 10.1007/s40744-017-0077-z.

Rheumatoid Arthritis

Outcomes Reported in Prospective Long-Term Observational Studies and Registries of Patients with Rheumatoid Arthritis Worldwide: An OMERACT Systematic Review

Arthritis Care Res (Hoboken).

Lopez-Olivo MA, Zogala RJ, des Bordes J, Zamora NV, Christensen R, Rai D, Goel N, Carmona L, Pratt G, Strand V, Suarez-Almazor ME

doi: 10.1002/acr.24163.

Rheumatoid Arthritis

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

Arthritis Rheumatol.

Charles-Schoeman C, DeMasi R, Valdez H, Soma K, Hwang LJ, Boy MG, Biswas P, McInnes IB

doi: 10.1002/art.40911.

Rheumatoid Arthritis

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Arthritis Res Ther.

Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, Mojcik C, DeMasi R, Strengholt S, Kwok K, Lazariciu I, Wang L, Cohen S

doi: 10.1186/s13075-019-1866-2.

Rheumatoid Arthritis

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

Ann Rheum Dis.

Emery P, Vencovský J, Sylwestrzak A, Leszczyński P, Porawska W, Stasiuk B, Hilt J, Mosterova Z, Cheong SY, Ghil J

doi: 10.1136/annrheumdis-

Rheumatoid Arthritis

The effect of treatments for rheumatoid arthritis on endothelial dysfunction evaluated by flow-mediated vasodilation in patients with rheumatoid arthritis

Curr Vasc Pharmacol.

Kotani K, Miyamoto M, Ando H

Rheumatoid Arthritis

Safety and Immunogenicity of Rituximab Biosimilar GP2013 After Switch from Reference Rituximab in Patients with Active Rheumatoid Arthritis

Arthritis Care Res (Hoboken).

Tony HP, Krüger K, Cohen S, Schulze-Koops H, Kivitz A, Jeka S, Vereckei E, Cen L, Kring L, Kollins D

doi: 10.1002/acr.23771.

Rheumatoid Arthritis

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

Arthritis Res Ther.

Cohen S, Pablos JL, Pavelka K, Müller GA, Matsumoto A, Kivitz A, Wang H, Krishnan E

doi: 10.1186/s13075-019-1857-3.

Related content

Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry

Outcomes Reported in Prospective Long-Term Observational Studies and Registries of Patients with Rheumatoid Arthritis Worldwide: An OMERACT Systematic Review

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

The effect of treatments for rheumatoid arthritis on endothelial dysfunction evaluated by flow-mediated vasodilation in patients with rheumatoid arthritis

Safety and Immunogenicity of Rituximab Biosimilar GP2013 After Switch from Reference Rituximab in Patients with Active Rheumatoid Arthritis

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis